NCT04478942View on ClinicalTrials.gov

PROMMO Trial: Oral Misoprostol vs IV Oxytocin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

January 14, 2025

Study Completion Date

January 14, 2025

Conditions
Premature Rupture of MembraneInduction of Labor Affected Fetus / Newborn
Interventions
DRUG

Misoprostol Oral Product

Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.

DRUG

Intravenous Oxytocin

Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.

Trial Locations (1)

53705-2216

UnityPoint Health- Meriter Hospital, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT04478942 - PROMMO Trial: Oral Misoprostol vs IV Oxytocin | Biotech Hunter | Biotech Hunter